Idorsia stock

IDIA · SIX · CHF

Compare Idorsia
CHF 3.59Change from previous close: −4.27%Absolute change: −CHF 0.16

Close · November 20, 2026

Price history

+10.51% over the period

1 year: from CHF 3.24 (November 20, 2025) to CHF 3.59 (November 20, 2026), +10.51%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026CHF 3.59
October 30, 2026CHF 4.47
September 30, 2026CHF 4.65
August 31, 2026CHF 4.94
July 31, 2026CHF 6.11
June 30, 2026CHF 6.86
May 29, 2026CHF 4.47
April 30, 2026CHF 3.68
March 31, 2026CHF 3.47
February 27, 2026CHF 3.91
January 30, 2026CHF 3.65
December 30, 2025CHF 4.26
November 28, 2025CHF 3.20
November 20, 2025CHF 3.24

At a glance

  • The company

    Biopharmaceutical company discovering and developing drugs for CNS, cardiovascular, immunological and orphan diseases

  • Latest results

    Quarter to September 30, 2026 · EPS -CHF 0.17 (estimate -CHF 0.28)

TickerLandia's take on Idorsia

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 2.80
52-wk highCHF 7.56

−52.57% from the 52-week high

Analysts · 3 analysts

Average targetCHF 5.00+39.43% vs. price

Buy 2 · Hold 1 · Sell 0 · Buy

TickerLandia Fingerprint: Idorsia

Compared with similar companies: very low earnings stability and very high risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Idorsia is pricier than similar companies

Idorsia's Forward P/E: 70.6, +35% against the median of a group of 6 similar companies (52.3).

Compared with 6 similar companies

Idorsia's metrics compared with similar companies
MetricIdorsiaPosition in the groupBand
Forward P/E70.6Middle
Operating margin-68.4%Middle
ROE23.9%Middle
Debt/equity-1.08Low
Net margin-128.8%Low

Grey band: the middle half of the group; tick: the median; dot: Idorsia. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

CHF 61.92M

Latest quarter · Q3 2026

Net income

-CHF 53.02M

Latest quarter · Q3 2026

Quarterly net margin

-85.6%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
CHF 1.05B
EPS
-CHF 1.15
Volume
680.03K
Daily trading
€3.62M

How Idorsia is changing

All results
  • Revenue grew 25.2% a year on average over the last 5 years

  • Operating margin rose from −825.2% to −52.8%

  • Shares outstanding up 50.3% in 5 years

Returns

Idorsia returns

CHF 1,000 invested in Idorsia 5 years ago, on November 22, 2021, would be worth CHF 215 today: −78.51% in total, −26.50% per year. This is the price return only: dividends are excluded.

PeriodIdorsiaSMICHF 1,000 becomes
1 month−15.50%+0.65%CHF 845
6 months−10.26%+8.75%CHF 897
Year to date−15.72%+9.83%CHF 843
1 year+10.51%+16.18%CHF 1,105
3 years+84.09%+35.68%CHF 1,841
5 years−78.51%+16.48%CHF 215

Over the last 6 months it has done better than 10% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Idorsia: technical analysis

Idorsia shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 89.2% below its all-time closing high (CHF 33.17, January 24, 2020).

Trend
No clear trend
RSI (14 sessions)
29
Below 30: a strong fall in a short time
vs 200-session average
−22.28%

Active signals

  • Close below the low of the previous 55 sessions.

    since November 19, 2026

  • RSI below 30: the stock has fallen a lot in a short time.

Support and resistance

Price areas where Idorsia has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. ResistanceCHF 4.14+15.45%2 touches, last on April 28, 2026
  2. ResistanceCHF 3.98+11.02%3 touches, last on October 19, 2026
  3. ResistanceCHF 3.83+6.77%4 touches, last on May 20, 2026
  4. Last priceCHF 3.59
  5. SupportCHF 3.43−4.48%3 touches, last on April 28, 2026
  6. SupportCHF 3.30−8.05%2 touches, last on March 6, 2026
  7. SupportCHF 2.83−21.22%2 touches, last on March 16, 2026

Volatility and risk

Over the last year it has moved roughly in line with the SMI.

Beta (1 year) vs SMI
0.84
Volatility (60 sessions, annualised)
48.4%
Largest fall in the last year
−47.95%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Idorsia: seasonality

Average monthly price change over 10 years

+0.4%Jan+8.5%Feb−4.3%Mar−0.8%Apr+10.7%May+5.9%Jun+2.9%Jul−2.3%Aug−5.8%Sep−10.4%Oct+0.3%Nov+6.9%Dec

Over the last 10 years, the strongest month for Idorsia has been May: +10.70% on average, positive in 7 years out of 9. The weakest has been October: −10.41% on average, positive in 2 years out of 10. November, the current month, has been positive in 4 years out of 9 (+0.32% on average).

Show chart data
MonthAverageMedianPositive years
January+0.37%+5.67%6 of 9
February+8.49%−8.26%3 of 9
March−4.31%−1.56%3 of 9
April−0.81%+0.26%5 of 9
May+10.70%+4.66%7 of 9
June+5.88%+3.70%5 of 9
July+2.91%−5.48%3 of 10
August−2.34%−3.40%3 of 10
September−5.79%−6.85%3 of 10
October−10.41%−12.60%2 of 10
November+0.32%−2.67%4 of 9
December+6.95%+10.33%5 of 9

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Idorsia and its competitors

QUVIVIQ (daridorexant), a treatment for insomnia, is the product through which many people know Idorsia Ltd, a biopharmaceutical company that discovers, develops and commercializes drugs for unmet medical needs.

Headquarters
Allschwil, Switzerland
Employees
424
Founded
2017
Chief executive
Roland Wandeler
Idorsia and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
IdorsiaIDIA$1.26B-68.4%—−10.26%
Pharma MarPHM$1.1B21.3%14.7−41.56%
Basilea PharmaceuticaBSLN$1.07B24.2%18.1+35.06%
PhilogenPHIL$905.96M79.1%3.67−5.63%
InventivaIVA$890.8M-5,980.9%—−33.75%
Pharming GroupPHARM$841.25M12.8%36.1−2.57%

Same industry or related industries, similar size. Compare Idorsia with its competitors · Full profile